NCT05359653View on ClinicalTrials.gov

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis RelapseMultiple Sclerosis Brain LesionMultiple Sclerosis Benign
Interventions
DRUG

Clemastine Fumarate

8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy

DRUG

Placebo

Matched sugar tablet

Trial Locations (1)

94107

RECRUITING

Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of California, San Francisco

OTHER